# Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children

> **NCT01125527** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 700 (actual)

## Conditions studied

- Haemophilus Influenzae Type b (Hib) Infection

## Interventions

- **BIOLOGICAL:** Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)
- **BIOLOGICAL:** Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)

## Key facts

- **NCT ID:** NCT01125527
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-10
- **Final completion:** 2010-04
- **Target enrollment:** 700 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01125527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01125527, "Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01125527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*